You are here: Industry Insights > Neurophth

News List

Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by EMA prnasia
January 28, 2022
Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth"), today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted the orphan drug designation (ODD)...
Neurophth Therapeutics Receives IND Clearance to Initiate Clinical Trial for China AAV-ND4 Gene Therapy NR082 in Leber Hereditary Optic Neuropathy prnasia
January 20, 2022
Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth"), today announced receiving the U.S. Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application...
Neurophth Raised Over $60 Million USD in Series-C Financing to Advance Gene Therapies prnasia
November 24, 2021
Neurophth Therapeutics Ltd., ("Neurophth"), a fully integrated genomic medicines company dedicated on seeking to improve lives through the curative potential of gene therapies...
Neurophth announced the first patient has been dosed in G.O.L.D. clinical trial for the gene therapy treatment of LHON prnasia
June 29, 2021
Neurophth Biotechnology Ltd., a fully-integrated genetic medicines company developing AAV-delivered gene therapies for the treatment of ocular diseases, announced that the first patient has been dosed in G.O.L.D. clinical trial for the treatment of ...
Neurophth Therapeutics and Hopstem Biotechnology Announce Strategic Partnership to Develop Human Induced Pluripotent Stem Cell-Derived Therapies for the Treatment of Ocular Diseases prnasia
June 02, 2021
Neurophth Biotechnology Ltd. announced a strategic partnership aiming to provide human iPSC-derived cell therapy for ocular diseases.
Neurophth Announces IND Approval by the NMPA for Leber Hereditary Optic Neuropathy Gene Therapy prnasia
April 02, 2021
Neurophth Biotechnology Ltd., a fully-integrated genomic medicines company developing adeno-associated viral (AAV)-delivered gene therapies for the treatment of ocular diseases, recently announced the Center for Drug Evaluation (CDE) of ...
Neurophth Closes RMB 400 Million Series B Financing prnasia
February 10, 2021
Neurophth Biotechnology Ltd. announced the closing of a RMB 400 million ($61.9 million USD) Series-B financing with a premier syndicate of investors, co-led by Guofang Capital and InnoVision Capital.
Neurophth and AAVnerGene Enter Strategic AAV Capsids Partnership for Next-Generation Ophthalmic Gene Therapy prnasia
January 19, 2021
Neurophth Therapeutics, Inc. and AAVnerGene Inc. today announced a strategic partnership to provide Neurophth with worldwide rights to mutually select adeno-associated virus (AAV) capsids for the next generation ophthalmic gene therapy.